Codexis, Inc.（CDXS）资讯与事件CDXSCodexis, Inc.

Codexis Expects Cash to Fund Operations Through 2028

The company said, "Codexis expects that its existing cash, cash equivalents, and short-term investments will be sufficient to fund its planned operations through the end of 2028. The financial guidance and cash runway projections include the expenses associated with the build out of the GMP production facility."

Codexis Reports Q2 Revenue of $14.92M, Beating Consensus

Reports Q2 revenue $14.92M, consensus $13.82M. "I am pleased with the strong financial results reported today for the second quarter of 2026," stated Alison Moore, President and Chief Executive Officer of Codexis. "In May, we presented new data at the TIDES US annual meeting demonstrating how the ECO Synthesis Manufacturing Platform enables control over stereochemistry in the manufacture of siRNA compounds which may enhance their potency and product quality. We also demonstrated our technology has the ability to initiate enzymatic RNA synthesis starting from a single nucleotide. In addition, our balance sheet was significantly strengthened by a capital raise of approximately $25 million in net proceeds, completed in July. We have made significant progress in the first half of 2026 in industrializing our ECO Synthesis Manufacturing Platform, and look forward to continued demonstration of the value of our technology to our customers in the second half."

Codexis Commences Underwritten Public Offering of Common Stock

Codexis announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering will be offered by Codexis. Piper Sandler and Cantor are acting as joint bookrunning managers for the offering. Craig-Hallum is acting as co-manager.